KALA BIO, INC. Retained Earnings
KALA BIO, INC. (KALA) had Retained Earnings of -$698.10 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-19
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$698.10M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$696.52M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$694.90M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$695.59M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$698.10M 10-Q · filed 2026-08-19 |
| 2026-03-31 | -$696.52M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$694.90M 10-Q · filed 2026-08-19 |
| 2025-09-30 | -$695.59M 10-Q · filed 2025-11-19 |
| 2025-06-30 | -$688.02M 10-Q · filed 2025-08-08 |
| 2025-03-31 | -$676.87M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$667.92M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$659.75M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$650.79M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$641.22M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$629.41M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$620.78M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$612.08M 10-Q · filed 2023-08-04 |
| 2023-03-31 | -$601.66M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$587.21M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$574.37M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$603.44M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$575.33M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$542.39M 10-K · filed 2023-03-03 |
| 2021-09-30 | -$494.82M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$466.69M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$430.19M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$399.78M 10-K · filed 2022-03-29 |
| 2020-09-30 | -$368.67M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$340.72M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$317.41M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$295.46M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$273.50M 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$250.32M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$226.50M 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$201.11M 10-K · filed 2020-02-12 |
| 2018-09-30 | -$175.89M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$160.29M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$145.67M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$134.37M 10-K · filed 2019-03-12 |
| 2017-09-30 | -$123.08M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$112.91M 10-Q · filed 2017-08-31 |
| 2016-12-31 | -$92.14M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |